Q1 EPS Estimate for Axsome Therapeutics Reduced by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Wednesday, February 25th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.70) for the quarter, down from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $260.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.73 EPS, FY2026 earnings at ($0.41) EPS, Q1 2027 earnings at $1.77 EPS, Q2 2027 earnings at $2.55 EPS, Q3 2027 earnings at $3.37 EPS, Q4 2027 earnings at $4.17 EPS and FY2027 earnings at $11.87 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.14. The business had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The company’s revenue was up 65.0% on a year-over-year basis.

Several other equities research analysts also recently commented on AXSM. Wolfe Research assumed coverage on shares of Axsome Therapeutics in a research report on Monday. They set an “outperform” rating and a $230.00 target price for the company. Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $219.00 to $222.00 and gave the company an “outperform” rating in a research note on Tuesday. Wells Fargo & Company increased their target price on shares of Axsome Therapeutics from $193.00 to $202.00 and gave the stock an “overweight” rating in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and set a $225.00 price target on shares of Axsome Therapeutics in a research report on Monday. Finally, Guggenheim upped their price target on shares of Axsome Therapeutics from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday. Seventeen analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $163.19 on Friday. Axsome Therapeutics has a twelve month low of $86.99 and a twelve month high of $191.50. The stock’s 50 day moving average is $175.55 and its 200-day moving average is $145.65. The company has a quick ratio of 1.50, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $8.35 billion, a price-to-earnings ratio of -44.22, a PEG ratio of 34.93 and a beta of 0.40.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors have recently bought and sold shares of AXSM. Kemnay Advisory Services Inc. bought a new stake in Axsome Therapeutics during the 4th quarter valued at approximately $31,000. Ameriflex Group Inc. bought a new position in Axsome Therapeutics during the 4th quarter valued at approximately $37,000. Versant Capital Management Inc increased its holdings in shares of Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after acquiring an additional 203 shares in the last quarter. GAMMA Investing LLC boosted its stake in Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after purchasing an additional 106 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its position in Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after purchasing an additional 235 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Axsome Therapeutics news, CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the completion of the transaction, the chief financial officer owned 42,588 shares of the company’s stock, valued at $8,003,136.96. This represents a 21.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Herriot Tabuteau sold 32,410 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $185.60, for a total value of $6,015,296.00. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,341,702.40. This represents a 81.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 308,874 shares of company stock valued at $51,390,805 over the last three months. Company insiders own 22.30% of the company’s stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $230 price target (≈41% upside vs. the $163 reference). New, bullish initiations often lift momentum and institutional interest. Wolfe Research initiation
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 target and published very bullish FY2027 EPS forecasts (FY2027 EPS = $11.87). That long‑range earnings trajectory and high target price support a higher valuation narrative for AXSM.
• Positive Sentiment: Axsome announced participation in multiple March investor conferences (TD Cowen, etc.), increasing management visibility and providing upcoming opportunities for updates and Q&A with investors. Investor conference schedule
• Positive Sentiment: Media coverage highlighting AXSM’s inclusion/performance in Nasdaq index funds and framing the stock as reaching new highs can attract momentum traders and passive flows. Kalkine article
• Neutral Sentiment: Reported short interest data for late February shows zero shares (and NaN changes) — the figures appear erroneous or not meaningful. No clear short‑sell pressure signal from these data.
• Negative Sentiment: HC Wainwright cut near‑term 2026 estimates sharply: Q1 2026 EPS from ($0.13) → ($0.70), Q2 2026 from $0.51 → ($0.41), Q3 2026 from $1.46 → ($0.05), Q4 2026 from $2.06 → $0.73, and FY2026 from $3.91 → ($0.41). Those downward revisions increase earnings uncertainty in the near term and could pressure sentiment among short‑horizon investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.